[ Price : $8.95]
FDA accepts for review a Bristol-Myers Squibb supplemental BLA for a subcutaneous formulation of Orencia (abatacept).[ Price : $8.95]
Vivus says it is planning a second quarter 2011 NDA submission for its erectile dysfunction drug TA-314 (avanafil) after reporting...[ Price : $8.95]
Cubist Pharmaceuticals petitions FDA to block approval of generic Cubicin (daptomycin) until potential ANDA submissions meet certa...[ Price : $8.95]
FDA's Gastroenterology and Urology Devices Panel votes to recommend wider use for Allergan's LAP-Band System for weight reduction ...[ Price : $8.95]
In a new Columbia Journalism Review article, FDA Webview editor Jim Dickinson tells how government press officers stole our freedo...[ Price : $8.95]
DDMAC says Allergan should stop using a Lumigan mailer directed at healthcare professionals because it allegedly contains unsubsta...[ Price : $8.95]
Seattle Genetics says it plans a first quarter 2011 BLA for brentuximab vedotin (SGN-35) for treating relapsed or refractory Hodgk...[ Price : $8.95]
Federal Register Notice: FDA seeks comments on requirements for persons exporting products that may not be marketed in the U.S.